Nothing Special   »   [go: up one dir, main page]

HUE048395T2 - Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára - Google Patents

Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára

Info

Publication number
HUE048395T2
HUE048395T2 HUE15806980A HUE15806980A HUE048395T2 HU E048395 T2 HUE048395 T2 HU E048395T2 HU E15806980 A HUE15806980 A HU E15806980A HU E15806980 A HUE15806980 A HU E15806980A HU E048395 T2 HUE048395 T2 HU E048395T2
Authority
HU
Hungary
Prior art keywords
pyridines
pyrrolo
imaging agents
neurofibrilary tangles
neurofibrilary
Prior art date
Application number
HUE15806980A
Other languages
English (en)
Inventor
Abbas Walji
Eric Hostetler
Thomas Greshock
Jing Li
Keith Moore
Idriss Bennacef
James Mulhearn
Harold Selnick
Yaode Wang
Kun Yang
Jianmin Fu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUE048395T2 publication Critical patent/HUE048395T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HUE15806980A 2014-06-13 2015-06-09 Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára HUE048395T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/079834 WO2015188368A1 (en) 2014-06-13 2014-06-13 Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles

Publications (1)

Publication Number Publication Date
HUE048395T2 true HUE048395T2 (hu) 2020-08-28

Family

ID=54832744

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15806980A HUE048395T2 (hu) 2014-06-13 2015-06-09 Pirrolo[2,3-C]piridinek mint képalkotó szerek neurofibrilláris fonatok számára

Country Status (15)

Country Link
US (2) US9808542B2 (hu)
EP (1) EP3154970B1 (hu)
JP (1) JP6513107B2 (hu)
KR (1) KR102478430B1 (hu)
CN (1) CN106661018B (hu)
AU (1) AU2015274843B2 (hu)
BR (1) BR112016028345B1 (hu)
CA (1) CA2948528C (hu)
DK (1) DK3154970T3 (hu)
ES (1) ES2763095T3 (hu)
HU (1) HUE048395T2 (hu)
MX (1) MX2016016384A (hu)
PL (1) PL3154970T3 (hu)
RU (1) RU2695373C2 (hu)
WO (2) WO2015188368A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190136125A (ko) 2012-12-21 2019-12-09 국립연구개발법인 양자과학기술연구개발기구 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
AU2017299219B2 (en) 2016-07-22 2022-12-22 Ac Immune Sa Compounds for imaging Tau protein aggregates
CN110691593B (zh) 2017-06-02 2023-05-02 富士胶片富山化学株式会社 脊髓小脑变性症预防或治疗剂
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
BR112019024878A2 (pt) * 2017-06-02 2020-06-16 Fujifilm Toyama Chemical Co., Ltd. Agente para prevenção ou tratamento de tauopatia
CA3067458C (en) 2017-06-02 2022-11-01 Fujifilm Toyama Chemical Co., Ltd. Agent for reducing amount of amyloid .beta. protein
WO2018221729A1 (ja) 2017-06-02 2018-12-06 富山化学工業株式会社 脳萎縮予防または治療剤
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
CN110343101B (zh) * 2018-04-04 2022-07-12 青岛福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
SG11202010946YA (en) * 2018-05-09 2020-12-30 Aprinoia Therapeutics Inc Heteroaryl compounds and uses thereof
CN108676007B (zh) * 2018-06-22 2020-06-26 厦门大学 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
TWI759962B (zh) 2019-11-13 2022-04-01 香港商新旭生技股份有限公司 用於降解tau蛋白聚集體的化合物及其用途
US20220008563A1 (en) * 2020-07-10 2022-01-13 The Regents Of The University Of California Radiolabelled and nonradiolabelled pegylated compounds and uses thereof
CN112939753B (zh) * 2020-09-15 2022-04-05 浙江大学 一种1-茚酮类化合物的合成方法
KR102240400B1 (ko) * 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물
CN112745299B (zh) * 2021-01-07 2022-01-25 温州大学 4-氰基-7,8-二氢异喹啉衍生物及其制备方法和应用
TWI782769B (zh) * 2021-10-28 2022-11-01 行政院原子能委員會核能研究所 一種新穎神經纖維糾結微管相關蛋白質Tau造影化合物、其製備方法及用途
CN114149425A (zh) * 2021-11-16 2022-03-08 上海应用技术大学 5-氟甲基吡啶衍生物和18-f同位素标记的5-氟甲基吡啶衍生物及其制备与应用
CN114276259B (zh) * 2022-01-04 2022-12-06 济川(上海)医学科技有限公司 一种马来酸二甲茚定关键中间体的制备方法
CN115417816B (zh) * 2022-09-05 2024-01-26 江苏南大光电材料股份有限公司 一种3,6-二溴-1-氯-异喹啉的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451566A (en) * 1993-11-17 1995-09-19 Zeneca Limited Herbicidal pyrrolopyridine compounds
ATE520692T1 (de) * 2004-10-07 2011-09-15 Merck Sharp & Dohme Thiazolyl-mglur5-antagonisten und verfahren zu ihrer verwendung
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
WO2008103615A1 (en) 2007-02-21 2008-08-28 Kalypsys, Inc. Isoquinolines useful as inducible nitric oxide synthase inhibitors
TW200902499A (en) * 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
US20110076230A1 (en) * 2008-05-30 2011-03-31 Barrow James C Novel Substituted Indoles
CA2760791C (en) 2009-05-07 2017-06-20 Intellikine, Inc. Heterocyclic compounds and uses thereof
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
US8684313B2 (en) 2011-02-02 2014-04-01 Ocean Rodeo Sports Inc. Inflatable kite with leading edge swept forwards at wingtip
US20140348748A1 (en) * 2011-09-16 2014-11-27 Lisheng Cai Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
WO2013181075A1 (en) * 2012-05-29 2013-12-05 Merck Sharp & Dohme Corp. Isotopically labeled biaryl urea compounds
CN103450152B (zh) * 2012-06-04 2015-11-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
GB201304526D0 (en) 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201404498D0 (en) * 2014-03-13 2014-04-30 Proximagen Ltd New compounds

Also Published As

Publication number Publication date
RU2695373C2 (ru) 2019-07-23
DK3154970T3 (da) 2020-01-20
CN106661018B (zh) 2019-07-19
EP3154970A2 (en) 2017-04-19
EP3154970A4 (en) 2017-11-15
BR112016028345B1 (pt) 2022-11-29
KR20170016481A (ko) 2017-02-13
US20170119912A1 (en) 2017-05-04
RU2019115483A (ru) 2019-06-13
US20180071412A1 (en) 2018-03-15
MX2016016384A (es) 2017-05-01
EP3154970B1 (en) 2019-11-06
CN106661018A (zh) 2017-05-10
PL3154970T3 (pl) 2020-04-30
CA2948528C (en) 2022-05-31
JP2017521387A (ja) 2017-08-03
WO2015191506A2 (en) 2015-12-17
US9808542B2 (en) 2017-11-07
BR112016028345A2 (pt) 2017-08-22
JP6513107B2 (ja) 2019-05-15
RU2016150404A3 (hu) 2018-11-30
WO2015191506A3 (en) 2016-02-04
AU2015274843A1 (en) 2016-11-10
WO2015188368A1 (en) 2015-12-17
BR112016028345A8 (pt) 2021-06-29
AU2015274843B2 (en) 2018-11-22
CA2948528A1 (en) 2015-12-17
ES2763095T3 (es) 2020-05-27
US10022461B2 (en) 2018-07-17
KR102478430B1 (ko) 2022-12-15
RU2016150404A (ru) 2018-07-18

Similar Documents

Publication Publication Date Title
PL3154970T3 (pl) Pirolo[2,3-c]pirydyny jako środki do obrazowania splątków neurofibrylarnych
IL261158B (en) Tetracyclic pyridone compounds as antivirals
IL275365A (en) 6-Azaindole compounds
IL247527A0 (en) Herbicidal preparations containing isoxazolo[4,5–b]pyridines
IL251164A0 (en) Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao
IL263511B (en) H1–pyrazolo[4, 3–b]pyridines as pde1 inhibitors
IL247599B (en) Formulation that suppresses the immune system
IL250682A0 (en) A method for the preparation of 2'-o-fucosyl lactose
HK1225723A1 (zh) 取代的咪唑並[1,2-a]吡啶甲酰胺及其用途
PL2949650T3 (pl) Syntetyczny sposób otrzymywania 1,2-benzoizotiazolin-3-onu
GB2531940B (en) Process for preparing methotrexate formulation
HK1255014A1 (zh) 製備取代5,6-二氫-6-苯基苯並[f]異喹啉-2-胺的方法
HRP20180585T1 (hr) Spojevi 2,7-diazaspiro[3.5]nonana
IL251166B (en) Imidazo–[4,5–c]pyridine derivatives as inhibitors of ssao
ZA201701093B (en) Aryl-triazolyl pyridines as pest control agents
DK3330264T3 (en) Pyridin substitueret 2-aminopyridin proteinkinase-inhibitorkrystal
GB201522532D0 (en) Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
SG10201600362SA (en) Methods For Optimising Parameters
HK1254355A1 (zh) Bace1抑制劑2-氨基-7a-苯基-3,4,4a,5,7,7a-六氫呋喃並[3,4-b]吡啶
HK1244277A1 (zh) 新的取代的三唑並嘧啶作為抗瘧藥